Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Consensus

—

Average target

$48.00

Implied upside

—

Analysts

—

Why Is IMCR Slightly Down Today?

Immunocore Holdings plc saw a modest decline of $0.04 (0.14%) following the release of its Q2 2026 earnings call transcript. The minimal price movement suggests investors are digesting the company's recent quarterly results and forward guidance with measured sentiment.

Bottom line: Immunocore's Q2 2026 earnings call generated minimal market reaction, suggesting investors are cautiously evaluating the company's progress without strong conviction in either direction. Shareholders should focus on upcoming clinical milestones, regulatory decisions, and commercial execution as key drivers of future stock performance.